Allogene Therapeutics (ALLO) Earnings Date & Reports

Industry: @Biotechnology

A.I. Advisor

published Earnings

ALLO is expected to report earnings to fall 4.91% to -33 cents per share on October 31

Allogene Therapeutics ALLO Stock Earnings Reports

Q3'24

Est.

$-0.33

Q2'24

Est.

$-0.35

Q1'24

Beat

by $0.03

Q4'23

Missed

by $0.06

Q3'23

Beat

by $0.15

The last earnings report on August 07 showed earnings per share of -34 cents, meeting the estimate of -34 cents. With 1.16M shares outstanding, the current market capitalization sits at 608.51M.

View a ticker or compare two or three

Compare

ALLO

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For ALLO
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile

Fundamentals

Details

Industry

Biotechnology

Address

210 East Grand Avenue

Phone

+1 650 457-2700

Employees

233

Web

https://www.allogene.com